Profusa (NASDAQ:PFSA) & Longevity Health (NASDAQ:XAGE) Financial Survey

Longevity Health (NASDAQ:XAGE) and Profusa (NASDAQ:PFSA) are both small-cap manufacturing companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a breakdown of recent recommendations for Longevity Health and Profusa, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Longevity Health	0	0	0	0	0.00
Profusa	1	0	0	0	1.00

Profitability

This table compares Longevity Health and Profusa’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Longevity Health	-682.67%	N/A	-261.90%
Profusa	N/A	N/A	-880.32%

Insider & Institutional Ownership

24.2% of Longevity Health shares are held by institutional investors. Comparatively, 9.8% of Profusa shares are held by institutional investors. 29.0% of Longevity Health shares are held by insiders. Comparatively, 11.4% of Profusa shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Longevity Health and Profusa”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Longevity Health	$1.05 million	0.49	-$10.37 million	($3.91)	-0.07
Profusa	N/A	N/A	-$8.71 million	($2.23)	-0.04

Profusa has lower revenue, but higher earnings than Longevity Health. Longevity Health is trading at a lower price-to-earnings ratio than Profusa, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Longevity Health has a beta of 0.37, indicating that its stock price is 63% less volatile than the S&P 500. Comparatively, Profusa has a beta of -0.14, indicating that its stock price is 114% less volatile than the S&P 500.

About Longevity Health

Carmell Therapeutics Corporation focuses on the development of plasma-based bioactive material (PBM) to stimulate tissue repair or growth after injury, disease, and aging. Its lead product candidate is CT-101 bone healing accelerant for tibia fracture healing, foot/ankle fusion, spinal fusion, dental bone graft substitute, and bone void filler; and tissue healing accelerant for androgenetic alopecia and chronic wound healing. The company was founded in 2008 and is based in Pittsburgh, Pennsylvania.

About Profusa

NorthView Acquisition Corporation does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It also intends to focus its search on businesses that are focused on healthcare sector. The company was incorporated in 2021 and is based in New York, New York. NorthView Acquisition Corporation is a subsidiary of NorthView Sponsor I, LLC.